Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback